ARBOR BIOTECHNOLOGIES
Dead / Abandoned — Abandoned — after ex parte appeal (as of 29 Jan 2025)
What this means for you
This application is over — abandoned 29 Jan 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97365239
- Mark type
- Stylized text
- Filed
- 15 Apr 2022
- Abandoned
- 29 Jan 2025
- Attorney of record
- Karen K. Won
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of genetic diseases and disorders, genomic diseases and disorders, and cancer; gene therapy products, namely, genetically engineered DNA molecules and gene delivery pharmaceuticals for use in the treatment of genetic diseases and disorders, genomic diseases and disorders, and cancer; cell therapy products, namely, cells for medical and clinical use
- Class 040 — Treatment of materials: Manufacturing of pharmaceuticals, gene therapy products, and cell therapy products for others
- Class 042 — Scientific and technological services: Pharmaceutical research and development; research and development in the fields of gene therapy and cell therapy
Owner
- Arbor Biotechnologies, Inc., Cambridge, MA, US
Prosecution history
- 06 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 06 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 06 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 06 Feb 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 06 Feb 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 06 Feb 2025 — ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
- 29 Jan 2025 — ABANDONMENT - AFTER EX PARTE APPEAL
- 29 Jan 2025 — EXPARTE APPEAL TERMINATED
- 20 Dec 2024 — EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
- 04 Nov 2024 — ASSIGNED TO EXAMINER
- 04 Nov 2024 — ASSIGNED TO EXAMINER
- 28 Feb 2024 — EX PARTE APPEAL-INSTITUTED
- 28 Feb 2024 — EXPARTE APPEAL RECEIVED AT TTAB
- 27 Nov 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 27 Nov 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED